MEI Pharma, Inc.
MEIP
$2.04
$0.042.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -- |
| Cost of Revenue | -98.34% | -46.11% | 82.42% | -63.39% | -74.27% |
| Gross Profit | 98.34% | -103.01% | -515.99% | 35.86% | -119.99% |
| SG&A Expenses | -71.31% | -48.11% | -59.14% | -33.98% | -3.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -80.64% | -47.42% | -30.65% | -53.38% | -48.56% |
| Operating Income | 80.64% | -109.50% | 20.43% | 35.30% | -214.85% |
| Income Before Tax | 75.80% | -114.20% | -83.53% | 40.88% | -207.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 75.80% | -114.20% | -83.53% | 40.88% | -207.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.80% | -114.20% | -83.53% | 40.88% | -207.90% |
| EBIT | 80.64% | -109.50% | 20.43% | 35.30% | -214.85% |
| EBITDA | 80.50% | -108.82% | 20.91% | 35.45% | -212.99% |
| EPS Basic | 75.80% | -114.20% | -83.52% | 40.88% | -207.90% |
| Normalized Basic EPS | 86.28% | -108.70% | 17.46% | 35.90% | -193.98% |
| EPS Diluted | 75.80% | -114.20% | -83.52% | 40.88% | -207.90% |
| Normalized Diluted EPS | 86.28% | -108.70% | 17.46% | 35.90% | -193.98% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |